ATHE News and Press, Alterity Therapeutics Limited From 03/14/23

2023-03-14 08:09:44 ET Alterity Therapeutics ( NASDAQ: ATHE ) said the composition of matter patent previously allowed by the U.S. Patent and Trademark Office (USPTO) was granted by the agency. The patent No. 11,603,364 titled, 'Compounds for and methods of treating dis...

– Composition of matter patent from USPTO covers more than 100 novel compounds targeting neurodegenerative diseases including Alzheimer’s – – Newly patented compounds and legacy asset PBT2 licensed to Professor Colin Masters for evaluation in Alzheimer’s a...

MELBOURNE, Australia and SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today a...

MELBOURNE, Australia and SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today an...

Appendix 4C - Q2 FY23 Quarterly Cash Flow Report PR Newswire Highlights: Expanded participation in ATH434 Phase 2 clinical trial with sites opened for recruitment in Australia , the United States , and Italy Presented compelling bioMUSE data at two pres...

Alterity Therapeutics ( NASDAQ: ATHE ) stock rose ~10% on Monday after the company said that a study published in the journal Neurotherapeutics showed that its drug ATH434 was neuroprotective in a genetic model of Parkinson’s disease (PD) in an animal model. The pub...

Alterity Therapeutics ( NASDAQ: ATHE ) is trading 3% higher premarket after it said it begun enrollment in Italy for its Phase 2 trial of ATH434 to treat Multiple System Atrophy ( MSA ). The study will test ATH434 treatment on neuroimaging and protein biomarkers to demonst...

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy PR Newswire U.S. now open for enrollment of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australi...

Biotechnology company Alterity Therapeutics ( NASDAQ: ATHE ) is set to implement a 1-for-10 reverse ADS split. The board approved a ratio change of its ADSs to ordinary shares from the current ADS ratio of 1 ADS representing 60 ordinary shares to 1 ADS representing 600 ordinary sh...

Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) PR Newswire MELBOURNE, Australia and SAN FRANCISCO , Jan. 6, 2023 /PRNewswire/ -- Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE), a biotechnology co...